Azitra files $3.5 million at-the-market stock offering with A.G.P.

Azitra, Inc. filed a prospectus supplement dated September 28, 2026 for an at-the-market offering of up to $3,503,232 in common stock. The company entered into a Sales Agreement dated September 28, 2026 with A.G.P./Alliance Global Partners covering the offer and sale of shares from time to time.¹ A.G.P. is entitled to a cash fee equal to 3.0% of gross proceeds from all sales.¹

Azitra's common stock trades on NYSE American under the symbol AZTR, and closed at $0.1680 per share on September 25, 2026.¹ As of that date, the company's public float held by non-affiliates was approximately $10,509,696, based on 60,603,742 shares outstanding, of which about 4,100,000 shares were held by affiliates.¹ Because the float sits below $75 million, Azitra is limited under Form S-3 rules to selling no more than one-third of its public float in primary offerings in any 12-month period.¹

On the clinical side, the filing confirms that in June 2026 the company paused enrollment of its ongoing Phase 1b trial of ATR-12 for Netherton syndrome for capital preservation, with no assurance it can resume the program or restart enrollment on a timely basis or at all.¹ Separately, Azitra dosed the first patient in its ATR-04 Phase 1/2 trial in the third quarter of 2025 and plans to announce initial Cohort 1 data around the fourth quarter of 2026.¹

On listing status, the company received a letter from NYSE Regulation on August 19, 2026 confirming it had regained compliance with NYSE American's continued listing standards,¹ though its stock has traded below $1.00 per share for a sustained period.¹ As of June 30, 2026, Azitra had total assets of $8.9 million and working capital of $5.9 million, and the company said proceeds from this offering plus cash on hand would not be sufficient to fund operations over at least the next 12 months.¹